Other
Research and development expense
Vertex Pharmaceuticals Research and development expense decreased by 1.2% to $961.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.8%, from $979.70M to $961.60M. Over 4 years (FY 2021 to FY 2025), Research and development expense shows an upward trend with a 19.2% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher spending typically signals a commitment to long-term innovation and future product pipelines, while significant cuts may signal a shift toward short-term profitability.
Detailed definition
This metric captures the investment in creating new products, improving existing technologies, and advancing internal ca...
Peer comparison
Standard metric for technology and hardware firms; highly comparable to R&D spending at peers.
Metric ID:
other_research_and_development_expense_excluding_acquire_88a3cdHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $448.70M | $467.00M | $567.80M | $601.10M | $600.10M | $645.00M | $694.10M | $742.60M | $785.70M | $810.00M | $824.60M | $789.10M | $966.60M | $875.90M | $998.70M | $979.70M | $978.40M | $977.70M | $973.70M | $961.60M |
| QoQ Change | — | +4.1% | +21.6% | +5.9% | -0.2% | +7.5% | +7.6% | +7.0% | +5.8% | +3.1% | +1.8% | -4.3% | +22.5% | -9.4% | +14.0% | -1.9% | -0.1% | -0.1% | -0.4% | -1.2% |
| YoY Change | — | — | — | — | +33.7% | +38.1% | +22.2% | +23.5% | +30.9% | +25.6% | +18.8% | +6.3% | +23.0% | +8.1% | +21.1% | +24.2% | +1.2% | +11.6% | -2.5% | -1.8% |
Range$448.70M – $998.70M
CAGR+17.4%
Avg YoY Growth+17.8%
Median YoY Growth+21.7%
Current Streak5 quarters decline
Research and development expense at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's research and development expense?
- Vertex Pharmaceuticals (VRTX) reported research and development expense of $961.60M in Q1 2026.
- How has Vertex Pharmaceuticals's research and development expense changed year-over-year?
- Vertex Pharmaceuticals's research and development expense decreased by 1.8% year-over-year, from $979.70M to $961.60M.
- What is the long-term trend for Vertex Pharmaceuticals's research and development expense?
- Over 4 years (2021 to 2025), Vertex Pharmaceuticals's research and development expense has grown at a 19.2% compound annual growth rate (CAGR), from $1.94B to $3.91B.
- What does research and development expense mean?
- Spending on innovation and product development.